checkAd

     148  0 Kommentare NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors - Seite 3

    Investor Contact:
    Alex Schwartz
    ir@ngmbio.com     		Media Contact:
    Liz Melone
    media@ngmbio.com
       

    1. Meyaard, Immunity, 1997
    2. Guo, Trans Med, 2020
    3. Cao, 2015, Biochem Biophys Res Commun
    4. Wang, Exp Ther Med, 2016
    5. Wu, CP Cancer, 2018
    6. Yang, Head & Neck, 2018
    7. Jingushi, Onc. Reports, 2018
    8. Peng, Nat Comm, 2020
    9. Lijun, Oncoimmunology, 2020


    Lesen Sie auch


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors - Seite 3 LAIR1, through interactions with tumor-associated collagens, may form a stromal checkpoint that imposes signaling-based immune suppression and impedes anti-tumor immunityNGM plans to initiate first-in-human testing of NGM438 in 4Q21NGM featured …

    Artikel zu den Werten

    Schreibe Deinen Kommentar

    Disclaimer